PT  - JOURNAL ARTICLE
AU  - Frangos, Eleni
AU  - Ceko, Marta
AU  - Wang, Binquan
AU  - Richards, Emily A.
AU  - Gracely, John L.
AU  - Colloca, Luana
AU  - Schweinhardt, Petra
AU  - Bushnell, M. Catherine
TI  - Neural effects of placebo analgesia in fibromyalgia patients and healthy individuals
AID  - 10.1101/2020.07.31.231191
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.07.31.231191
4099  - http://biorxiv.org/content/early/2020/08/03/2020.07.31.231191.short
4100  - http://biorxiv.org/content/early/2020/08/03/2020.07.31.231191.full
AB  - Placebo analgesia is hypothesized to involve top-down engagement of prefrontal regions that access endogenous pain inhibiting opioid pathways. Fibromyalgia (FM) patients have neuroanatomical and neurochemical alterations in pathways relevant to placebo analgesia. Thus, it remains unclear whether placebo analgesic mechanisms would differ in FM patients compared to healthy controls (HCs). Here, using placebo-analgesia-inducing paradigms that included verbal suggestions and conditioning manipulations, we examined whether behavioral and neural placebo analgesic responses differed between 32 FM patients and 46 age- and sex-matched HCs. Participants underwent a manipulation scan, where noxious high and low heat were paired with the control and placebo cream, respectively, and a placebo experimental scan with equal noxious heat temperatures. Before the experimental scan, each participant received saline or naloxone, an opioid receptor antagonist. Across all participants, the placebo condition decreased pain intensity and unpleasantness ratings, decreased activity within the right insula and bilateral secondary somatosensory cortex, and modulated the Neurologic Pain Signature. There were no differences between HCs and FM patients in pain intensity ratings or neural responses during the placebo condition. Despite the perceptual and neural effects of the placebo manipulation, prefrontal circuitry was not activated during the expectation period and the placebo analgesia was unaltered by naloxone, suggesting placebo effects were driven more by conditioning than expectation. Together, these findings suggest that placebo analgesia can occur in both HCs and chronic pain FM patients, without the involvement of opiodergic prefrontal modulatory networks.Competing Interest StatementThe authors have declared no competing interest.